➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Moodys
Express Scripts
Merck
Johnson and Johnson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 10,386,359

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,386,359
Title:Methods for determining whether a patient will achieve a response after radiation therapy
Abstract: Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).
Inventor(s): Paris; Francois (Nantes, FR), Dubois; Nolwenn (Nantes, FR), Rio; Emmanuel (Nantes, FR), Ripoche; Natacha (Nantes, FR)
Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE DE NANTES (Nantes, FR) UNIVERSITE D\'ANGERS (Angers, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS) (Paris, FR) INSTITUT DE CANCERLOGIE DE L\'OUEST--SITE RENE GAUDUCHEAU (Saint-Herblain, FR)
Application Number:15/313,338
Patent Claims:see list of patent claims

Details for Patent 10,386,359

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE DE NANTES (Nantes, FR) UNIVERSITE D\'ANGERS (Angers, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS) (Paris, FR) INSTITUT DE CANCERLOGIE 2034-05-23 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE DE NANTES (Nantes, FR) UNIVERSITE D\'ANGERS (Angers, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS) (Paris, FR) INSTITUT DE CANCERLOGIE 2034-05-23 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE DE NANTES (Nantes, FR) UNIVERSITE D\'ANGERS (Angers, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS) (Paris, FR) INSTITUT DE CANCERLOGIE 2034-05-23 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE DE NANTES (Nantes, FR) UNIVERSITE D\'ANGERS (Angers, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS) (Paris, FR) INSTITUT DE CANCERLOGIE 2034-05-23 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE DE NANTES (Nantes, FR) UNIVERSITE D\'ANGERS (Angers, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS) (Paris, FR) INSTITUT DE CANCERLOGIE 2034-05-23 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE DE NANTES (Nantes, FR) UNIVERSITE D\'ANGERS (Angers, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS) (Paris, FR) INSTITUT DE CANCERLOGIE 2034-05-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
McKesson
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.